慢性乙型肝炎和乙型肝炎肝硬化患者胃粘膜病变研究

doi:10.3969/j.issn.1672-5069.2021.06.032

Abstract

Abstract: Objective The aim of this study was to investigate gastric mucosal lesions in patients with hepatitis B and hepatitis B-induced liver cirrhosis. Methods 70 patients with chronic hepatitis B (CHB), 56 patients with liver cirrhosis and 50 healthy persons were enrolled in our hospital between January 2017 and January 2019, and all underwent gastroscopy. Serum PGI and PGII levels were detected by ELISA, and peripheral blood CD3⁺, CD4⁺ and CD8⁺ cells were detected by FCM. Results Serum PGI level in patients with hepatitis B-induced liver cirrhosis was(93.8±28.3)μg/L, significantly lower than [(135.7±21.6)μg/L, P<0.05] in healthy persons or [(116.3±32.4)μg/L, P<0.05] in patients with CHB, serum PGII level was (13.3±5.7)μg/L, significantly higher than [(9.2±2.4)μg/L, P<0.05] in healthy persons, and the ratio of serum PGI/PGII was (7.1±2.3), significantly lower than [(14.8±3.4), P<0.05] in healthy persons or [(9.6±2.9), P<0.05] in patients with CHB; the prevalences of chronic superficial gastritis in healthy persons, in patients with CHB and in patients with cirrhosis were 68.0%, 32.9% and 19.6%(P<0.05), and the incidences of mild, moderate and severe chronic atrophic gastritis in patients with cirrhosis were 37.5%, 25.0% and 17.9%, significantly different compared to 8.0%, 6.0% and 2.0% (P<0.05) in healthy persons or 37.1%, 11.4% and 5.7% (P<0.05) in patients with CHB; the percentage of peripheral blood CD3⁺ cells in patients with cirrhosis was (62.4±7.9)%, significantly lower than [(68.3±5.8)%, P<0.05] in healthy persons or [(66.4±7.4)%, P<0.05] in patients with cirrhosis, the percentage of CD4⁺ cells was (35.7±7.4)%, significantly lower than [(50.3±6.6)%, P<0.05] in healthy persons or [(45.4±6.4)%, P<0.05] in patients with CHB, while the percentage of CD8⁺ cells was (34.4±4.7)%, significantly higher than [(27.2±4.3), P<0.05] and the ratio of CD4⁺/CD8⁺ cells was (1.8±0.3), significantly lower than [(2.8±0.9), P<0.05] in healthy persons. Conclusion The chronic atrophic gastritis in patients with hepatitis B cirrhosis is common, serum PGI and PGII levels change obviously, and the mechanism involved needs further investigation.

Key words: Liver cirrhosis, Gastric mucosal lesions, Pepsinogen

Han Lichou, Xu Wang, Han Dan, et al. Observation of gastric mucosal lesions in patients with hepatitis B liver cirrhosis[J]. Journal of Practical Hepatology, 2021, 24(6): 895-898.

References

[1] Han X, Huang T, Han J. Cytokines derived from innate lymphoid cells assist helicobacter hepaticus to aggravate hepatocellular tumorigenesis in viral transgenic mice. Gut Pathog, 2019,11:23.
[2] 赵蕾, 李小丹, 刘淼. 拉米夫定与替比夫定阻断乙型肝炎病毒宫内感染的疗效和风险分析. 实用肝脏病杂志, 2020, 23(4): 496-499.
[3] Zhao SX, Li WC, Fu N, et al. Emperipolesis mediated by CD8⁺ T cells correlates with biliary epithelia cell injury in primary biliary cholangitis. J Cell Mol Med, 2020,24(2):1268-1275.
[4] Xuan ZH, Wang LH, Ling ZY, et al. Hepatitis B virus X protein modulates renal tubular epithelial cell-induced T-cell and macrophage responses. Immunol Cell Biol, 2015, 94(3):266-273.
[5] Boltjes A, Brouw ML, Biesta PJ, et al. Assessment of the effect of ribavirin on myeloid and plasmacytoid dendritic cells during interferon-based therapy of chronic hepatitis B patients. Mol Immunol, 2013,53(1-2):72-78.
[6] Morisawa T, Namikawa M, Umeda M. Gastric emphysema with hepatic portal venous gas secondary to acute gastric mucosal lesion. Clin Gastroenterol Hepatol, 2020,S1542-3565(20):30970-30978.
[7] Kim Y S, Lee J H, Song J, et al. Gastroprotective effects of inulae flos on hcl/ethanol-induced gastric ulcers in rats. Molecules, 2020, 25(23):5623.
[8] Tu H, Sun L, Dong X, et al. Temporal changes in serum biomarkers and risk for progression of gastric precancerous lesions: a longitudinal study. Int J Cancer, 2015,136(2):425-434.
[9] Wang X, Lu B, Meng L, et al. The correlation between histological gastritis staging- 'OLGA/OLGIM' and serum pepsinogen test in assessment of gastric atrophy/intestinal metaplasia in China. Scand J Gastroenterol,2017,52(8):822-827.
[10] 陈红英, 丁洁, 游晶,等. 慢性乙型肝炎病毒感染者血清流行病学研究. 中国全科医学, 2017, 8(10):54-57,62.
[11] 孙雪飞, 何旭. 慢性萎缩性胃炎的胃镜下表现与病理诊断. 实用临床医药杂志, 2017(1):194-202.
[12] Behairy BE, Nermine E, Magdy A, et al. Expression of intrahepatic CD3, CD4, and CD8 T cells in biliary atresia. Clin Exp Hepatol,2018, 4(1):7-12.
[13] Nakiboneka R, Mugaba S, Auma BO, et al. Interferon gamma (IFN-γ) negative CD4⁺ and CD8⁺ T-cells can produce immune mediators in response to viral antigens. Vaccine,2019,37(1):113-122.
[14] 樊巧, 冯红军, 周环宇,等. 慢性乙型肝炎患者胃黏膜损伤中胃黏液sIgA的变化研究. 中华医院感染学杂志, 2016, 26(17):3892-3894.
[15] Carrilho FJ, Mattos AA, Vianey AF, et al. Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma. Arq Gastroenterol, 2015,52(Suppl 1):2-14.
[16] Hashimoto K, Suzuki A M, Santos A D, et al. CAGE profiling of ncRNAs in hepatocellular carcinoma reveals widespread activation of retroviral LTR promoters in virus-induced tumors. Genome Res, 2015, 25(12):1812-1824.
[17] Jie P, Jing Z, Qi FZ, et al. A radiomics nomogram for preoperative prediction of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma. Diagn Interv Radio, 2018, 24(3):121-127.
[18] Dang SC, Wang H, Zhang JX, et al. Are gastric mucosal macrophages responsible for gastric injury in acute pancreatitis? World J Gastroenterol,2015, 21(9):2651-2657.
[19] Masullo M, Mari A, Cerulli A, et al. Quali-quantitative analysis of the phenolic fraction of the flowers of Corylus avellana, source of the Italian PGI product "Nocciola di Giffoni": Isolation of antioxidant diarylheptanoids. Phytochemistry, 2016,130:273-281.
[20] Muhsen K, Sinnreich R, Merom D, et al. Prevalence and determinants of serological evidence of atrophic gastritis among Arab and Jewish residents of Jerusalem: a cross-sectional study. BMJ Open, 2019,9(1):e024689.
[21] Zoalfaghari A, Aletaha N, Roushan N, et al. Accuracy of pepsinogens for early diagnosis of atrophic gastritis and gastric cancer in Iranian population.Med J Islam Repub Iran, 2014, 28(1):150-150.

Observation of gastric mucosal lesions in patients with hepatitis B liver cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Shi Cuicui, Liu Yanjun, Zhang Ruinan, et al. Dyslipidemia in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 859-862.
[2]	Liu Mei, Shi Yonghong, Ying Juan, et al. Prevalence of nosocomial infection and resistance of pathogens in patients with decompensated liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 863-866.
[3]	Liu Yuling, Zhen Zengguo, Wang Huijuan, et al. Effects of probiotics on intestinal barrier function of patients with liver cirrhosis complicated by spontaneous bacterial peritonitis [J]. Journal of Practical Hepatology, 2021, 24(6): 867-870.
[4]	Xing Li, Du Qianying, Jiang Yanli, et al. Impact of segmented injection of contrast agent on hepatic vein imaging by CT angiography in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 871-874.
[5]	Huang Liou, Wu Chunrong, Xu Dan, et al. Efficacy of continuous renal replacement therapy without heparinization in patients with liver cirrhosis complicated by hepatic encephalopathy [J]. Journal of Practical Hepatology, 2021, 24(6): 875-878.
[6]	Ye Dong, Zhang Junxia, LiJie, et al. Risk factors of rebleeding in hepatitis B liver cirrhotics with esophageal varices bleeding after endoscopic variceal ligation [J]. Journal of Practical Hepatology, 2021, 24(6): 879-882.
[7]	Han Chengmei, Han Yongfeng, Wang Chunhua. Risk factors for acute kidney injury in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 883-886.
[8]	Wang Jing, Bi Ning, Fang Liang, et al. Efficacy of transarterial intrahepatic transplantation of autologous bone marrow stem cells in the treatment of patients with decompensated hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 887-890.
[9]	Xue Kui, Xu Yinhai, Zhang Jian. Changes of serum thrombopoietin levels and its relationship with peripheral blood platelet counts in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 891-894.
[10]	Shu Qinghua, Zhang Nannan, Ge Yongsheng. Impact of HCV genotypes on the treatment response of recombinant human interferon α-2a in patients with chronic hepatitis C and hepatitis C liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 899-902.
[11]	Tan Fenglei, Wu Liangliang, Deng Zerun, et al. Nocturnal snack in patients with liver cirrhosis: a Meta analysis [J]. Journal of Practical Hepatology, 2021, 24(5): 625-628.
[12]	Li Wei, Song Weidong, Xie Batu Baiyin. Efficacy of esophageal variceal ligation and transjugular intrahepatic portosystemic shunt in treatment of patients with liver cirrhosis and esophageal varices bleeding [J]. Journal of Practical Hepatology, 2021, 24(5): 629-632.
[13]	Wu Qiong, Sun Yang, Liu Na, et al. Implication of peripheral blood leukocyte VCS parameters in patients with decompensated liver cirrhosis and sepsis [J]. Journal of Practical Hepatology, 2021, 24(5): 633-636.
[14]	Liu Yuling, Zhen Zengguo, Wang Huijuan, et al. Predicting value of serum ascites albumin gradient on esophageal variceal bleeding risk in patients with decompensated hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(5): 637-640.
[15]	Ji Minyou, Li Chao, Zhao Xingzhong, et al. Intestinal flora changes in patients with hepatitis B-induced liver cirrhosis after entecavir and glycyrrhizin combination treatment [J]. Journal of Practical Hepatology, 2021, 24(5): 641-644.